 Participants who have a Her-2neu positive cancer will potentially be eligible to receive trastuzumab therapy for 1 year. This medicine is given through a vein either once a week over 30 minutes or once every 3 weeks over 30 minutes. Your doctor will discuss whether this medicine is appropriate for you. 